Search Results - Gheath Al-Atrash

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center

    Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center by Betül Oran, Peter Thall, Amin Alousi, Gheath Al-Atrash, Rohtesh Mehta, David Marin, Partow Kebriaei, Uday Popat, Roland Bassett, Qaiser Bashir, Jin Im, Amanda Olson, Jessica Jewell, Portia Smallbone, Elizabeth Shpall, Richard Champlin

    Published 2025-07-01

    This phase 2, single-center clinical trial evaluated the efficacy and safety of guadecitabine, with or without donor lymphocyte infusion, following allogeneic stem cell transplantation (allo-SCT) in adult patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The study had t...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort

    Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort by Ignacio I Wistuba, Jianhua Zhang, Anup Kasi, Hong Chen, Seunghee Kim-Schulze, Holden T Maecker, Elad Sharon, Razelle Kurzrock, Sacha Gnjatic, Young Kwang Chae, Jiexin Zhang, Jianjun Zhang, Sandip Pravin Patel, Cara L Haymaker, Megan Othus, Charles Blanke, Edwin Parra, Gheath Al-Atrash, Caroline Duault, J Jack Lee, Helen X Chen, Edgar Gonzalez-Kozlova, Dzifa Yawa Duose, Luisa Solis Soto, Ganiraju Manyam, Christopher W Ryan, Jillian Fisher, Bhavana Konda, Mark Walshauser, Caddie Laberiano Fernandez, Raja Luthra, Christine M Magner

    Published 2025-06-01

    Purpose SWOG S1609 Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) studied the efficacy of ipilimumab combined with nivolumab across multiple rare tumor types. We report the results of the pancreatic neuroendocrine neoplasm (PNEN) cohort.Experimental design Treatment consisted of ipili...

    Full description

    Get full text
    Article

    Save to List
    Saved in:

Search Tools: